Quali-quantitative synthesis between clinical trials and patents on Covid-19 associated with CRISPR

• Autor(a) principal: Meneghin, Rogério Almeida
• Data de Publicação: 2023
• Outros Autores: Winter, Eduardo, Cortines , Juliana Reis, Angeli, Renata
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Brazilian Journal of Health Review
• DOI: 10.34119/bjhrv6n1-157
• Texto Completo: https://ojs.brazilianjournals.com.br/ojs/index.php/BJHR/article/view/56719
• topic: ACE2; clinical trial; Covid-19; CRISPR-Cas; patent; spike

Introduction: The work presents a comparative analysis between clinical trials and patent families on COVID-19 associated with CRISPR-Cas, ACE2 and Spike worldwide. Methods: From a total of 7815 clinical trials dedicated to COVID-19, 238 clinical trials related to CRISPR-Cas, ACE2 and Spike were identified, and 112 patent families. For the recovery of clinical trials and patent families, the ICTRP® platform of the World Health Organization, the ORBIT INTELLIGENCE® system from Questel® and the INPI COVID-19 Observatory were used, respectively. Results: Through quantitative and qualitative analysis and synthesis, a pattern of insignificant similarity was observed between the institutions that sponsor clinical trials and holders of patent families, among other correlated indicators. Conclusions: In summary, it is suggested that new public policies be created to encourage synergy between clinical trials and patents, both national, in order to induce a safe path to technological independence and, consequently, better performance in combating COVID-19 associated with CRISPR-Cas, ACE2 and Spike in Brazil.